Sorry, there are no news articles available for .

Latest News By Stage


A

Sorry, there are no articles available for this cancer stage.

More A

Acute Lymphoblastic Leukemia

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (August 22, 2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children... Continue Reading

More Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (January 31, 2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)... Continue Reading

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia (August 10, 2017)

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic,... Continue Reading

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia (June 20, 2017)

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers,... Continue Reading

More Acute Myeloid Leukemia

Acute Promyelocytic Leukemia

Sorry, there are no articles available for this cancer stage.

More Acute Promyelocytic Leukemia

Adjuvant (I-III, A-C) Colon Cancer

Sorry, there are no articles available for this cancer stage.

More Adjuvant (I-III, A-C) Colon Cancer

Adult Acute Lymphoblastic Leukemia

Sorry, there are no articles available for this cancer stage.

More Adult Acute Lymphoblastic Leukemia

Advanced Stage Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Advanced Stage Hodgkin's Lymphoma

Advisory Complementary Alternative Medicine

Sorry, there are no articles available for this cancer stage.

More Advisory Complementary Alternative Medicine

Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

All Cancer Types

New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style (July 19, 2017)

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA... Continue Reading

More All Cancer Types

Allogeneic Stem Cell Transplant

Sorry, there are no articles available for this cancer stage.

More Allogeneic Stem Cell Transplant

Alphabetical Sort

Sorry, there are no articles available for this cancer stage.

More Alphabetical Sort

Alternative Medical Systems Complementary Alternative Medicine

Sorry, there are no articles available for this cancer stage.

More Alternative Medical Systems Complementary Alternative Medicine

Anal Cancer

Sorry, there are no articles available for this cancer stage.

More Anal Cancer

Autologous Stem Cell Transplant

Sorry, there are no articles available for this cancer stage.

More Autologous Stem Cell Transplant

B

Sorry, there are no articles available for this cancer stage.

More B

Barrett's Esophagus Esophageal Cancer

Sorry, there are no articles available for this cancer stage.

More Barrett's Esophagus Esophageal Cancer

Biologic-Orthomolecular Therapies Complementary Alternative Medicine

Sorry, there are no articles available for this cancer stage.

More Biologic-Orthomolecular Therapies Complementary Alternative Medicine

Biological Therapy

Sorry, there are no articles available for this cancer stage.

More Biological Therapy

Bladder Cancer

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer (June 6, 2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall... Continue Reading

U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer (May 4, 2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative... Continue Reading

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer (April 3, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint... Continue Reading

Keytruda Improves Survival of Advanced Bladder Cancer (February 26, 2018)

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary... Continue Reading

More Bladder Cancer

Bone Cancer

Sorry, there are no articles available for this cancer stage.

More Bone Cancer

Brain Cancer

First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain (September 13, 2018)

Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, TX – September 13, 2018 – In the ongoing... Continue Reading

Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors (July 6, 2018)

A “smart bomb” oncolytic adenovirus appears to induce dramatic responses with long-term survival in recurrent high-grade gliomas, according to the early results of a study published in The Journal of Clinical Oncology. Glioblastoma is the... Continue Reading

Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported (May 30, 2018)

Northwest Biotherapeutics, developer of DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain... Continue Reading

Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit (May 29, 2018)

The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month. Collaborators from organizations including Roswell Park Comprehensive... Continue Reading

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers (August 2, 2017)

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric... Continue Reading

More Brain Cancer

Breast Cancer

What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer? (July 25, 2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion of an initial 5 years of treatment. The optimal... Continue Reading

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer (July 23, 2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor... Continue Reading

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients (July 9, 2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence... Continue Reading

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation (June 21, 2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy... Continue Reading

Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer (April 19, 2018)

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant differences in effectiveness or safety, For... Continue Reading

More Breast Cancer

C

Sorry, there are no articles available for this cancer stage.

More C

Cancer Dictionary

Sorry, there are no articles available for this cancer stage.

More Cancer Dictionary

Carcinoma In Situ Breast cancer

Sorry, there are no articles available for this cancer stage.

More Carcinoma In Situ Breast cancer

Cervical Cancer

FDA Approves Merck’s Keytruda® for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (June 18, 2018)

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1.  Keytruda is the... Continue Reading

Questions to Ask Before Radiation Therapy for the Treatment of Cervical Cancer (December 13, 2017)

Radiation therapy, or radiotherapy, is a common way to treat cervical cancer. Doctors who specialize in treating cancers with radiation are known as radiation oncologists. During radiation therapy, high-energy x-rays are used to kill cancer cells. Radiation... Continue Reading

Managment of the Side Effects of Radiation for Cervical Cancer (December 7, 2017)

Radiation therapy, or radiotherapy, is a common way to treat cervical cancer. With any treatment of cancer you must first understand your responsibility and your medical team’s role as well as explore treatment options and get a second opinion(s) before... Continue Reading

What You Should Know About the Side Effects of Surgery for Cervical Cancer (December 6, 2017)

A hysterectomy is a common surgical treatment of early stage cancer and precancerous disease of the cervix in women. With any treatment of cancer it is important to first understand your responsibility and your medical team’s role as well as explore... Continue Reading

Cervical Cancer Survivors Frequently Suffer From Long-Term Side Effects of Treatment (August 17, 2017)

According to a new study around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes.1 Cervical cancer affects more than 500,000 women around the world each year with an average... Continue Reading

More Cervical Cancer

Chemotherapy

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer (June 19, 2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has... Continue Reading

Head and Neck Cancer Patients at Risk of Cognitive Problems Following Treatment (January 8, 2018)

CancerConnect News: Patients who survive head and neck cancer may be more likely to experience declines in mental function according to the results of a recent study. The findings are drawn from cognitive assessments for 80 survivors of head and neck... Continue Reading

Cervical Cancer Survivors Frequently Suffer From Long-Term Side Effects of Treatment (August 17, 2017)

According to a new study around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes.1 Cervical cancer affects more than 500,000 women around the world each year with an average... Continue Reading

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (July 26, 2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State... Continue Reading

Shorter Duration Chemotherapy Possible for Early Stage Colon Cancer (June 26, 2017)

Many colon cancer patients can cut their chemotherapy regimen in half, improving their quality of life and reducing their chances of having debilitating side effects, according to the results of a major study released at the American Society of Clinical... Continue Reading

More Chemotherapy

Childhood Acute Lymphoblastic Leukemia

Sorry, there are no articles available for this cancer stage.

More Childhood Acute Lymphoblastic Leukemia

Chronic Lymphoblastic Leukemia

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

More Chronic Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has... Continue Reading

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (September 11, 2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

More Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (June 14, 2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients... Continue Reading

More Chronic Myeloid Leukemia

Clinical Trials Database

Sorry, there are no articles available for this cancer stage.

More Clinical Trials Database

Colon Cancer

Many Early Onset Colon Cancers are Caused by Genetic Mutations Passed Through Families (April 25, 2018)

CancerConnect News: One in every six colorectal cancer patients (16 percent) diagnosed under age 50 has at least one inherited genetic mutation that increases his or her cancer risk and many of these mutations could go undetected with the current screening... Continue Reading

Managing Side Effects From EGFR Inhibitors (April 10, 2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading

Diagnosed with Colon Cancer: 10 Tips on How to Get The Most From Your Doctor (February 21, 2018)

1) Choose Your Doctor Carefully Medical oncologists are the primary doctors involved with colon cancer and work in collaboration with surgeons and gastroenterologists. Pick a medical oncologist carefully, rely on people you trust including nurses and... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (January 8, 2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

More Colon Cancer

Complementary Alternative Medicine

Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer (December 14, 2017)

According to a well designed study presented at the 2017 San Antonio Breast Cancer Symposium acupuncture is effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.1 Stiffness and... Continue Reading

Alternative Medicine Used Alone Appears to Reduce Survival Rates in Cancer Patients (August 16, 2017)

Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center... Continue Reading

More Complementary Alternative Medicine

Corticosteroid

Sorry, there are no articles available for this cancer stage.

More Corticosteroid

D

Sorry, there are no articles available for this cancer stage.

More D

Drug Dictionary

Sorry, there are no articles available for this cancer stage.

More Drug Dictionary

E

Sorry, there are no articles available for this cancer stage.

More E

Early Stage Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Early Stage Hodgkin's Lymphoma

Early Stage I-II (A-B) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Early Stage I-II (A-B) Prostate Cancer

Esophageal Cancer

Keytruda Promising in PD-L1 Esophageal Cancer (February 13, 2018)

CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About Keytruda Keytruda is a monoclonal antibody that helps... Continue Reading

Diagnosed with Esophageal Cancer: 10 Tips on How to Get The Most From Your Doctor (December 1, 2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with esophageal cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including... Continue Reading

New Standard of Care for Treatment of Resectable Gastric Cancer (October 3, 2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable... Continue Reading

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer (September 25, 2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors,... Continue Reading

More Esophageal Cancer

Ewing's Sarcoma Overview

Sorry, there are no articles available for this cancer stage.

More Ewing's Sarcoma Overview

Extensive Lung Cancer - Small Cell

Sorry, there are no articles available for this cancer stage.

More Extensive Lung Cancer - Small Cell

F

Sorry, there are no articles available for this cancer stage.

More F

Follicular Lymphoma

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading

More Follicular Lymphoma

G

Sorry, there are no articles available for this cancer stage.

More G

Gastric Cancer

Diagnosed with Gastric Cancer: 10 Tips on How to Get The Most From Your Doctor (December 21, 2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with gastric cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including nurses... Continue Reading

New Standard of Care for Treatment of Resectable Gastric Cancer (October 3, 2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable... Continue Reading

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer (September 25, 2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors,... Continue Reading

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer (September 18, 2017)

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach... Continue Reading

More Gastric Cancer

Gene Therapy

Sorry, there are no articles available for this cancer stage.

More Gene Therapy

General

AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer (September 4, 2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved... Continue Reading

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors (August 2, 2018)

The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and other tissue areas. About Pheochromocytoma and Paraganglioma Pheochromocytomas... Continue Reading

FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults (May 24, 2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of... Continue Reading

FDA Approves Aimovig, A Novel Preventive Treatment for Migraine Headaches (May 21, 2018)

According to Dr. Jessica Ailani, MD, associate professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, migraines affect over 36 million people in the U.S. yet they are still a poorly... Continue Reading

What is a Venous Access Device and What Types are Used for Cancer Patients? (May 9, 2018)

A venous access device (VAD) is a surgically implanted device that provides long-term access to a major vein. A VAD can be useful for patients undergoing systemic treatment with precision cancer medicines or chemotherapy because it allows for a single... Continue Reading

More General

General Bone Cancer

Sorry, there are no articles available for this cancer stage.

More General Bone Cancer

General Brain Cancer

Sorry, there are no articles available for this cancer stage.

More General Brain Cancer

General Complementary Alternative Medicine

Sorry, there are no articles available for this cancer stage.

More General Complementary Alternative Medicine

General Gene Therapy

Sorry, there are no articles available for this cancer stage.

More General Gene Therapy

General Head and Neck Cancer

Sorry, there are no articles available for this cancer stage.

More General Head and Neck Cancer

General HIV Related Cancers

Sorry, there are no articles available for this cancer stage.

More General HIV Related Cancers

General Lung Cancer

Sorry, there are no articles available for this cancer stage.

More General Lung Cancer

General Malignant Mesothelioma

Sorry, there are no articles available for this cancer stage.

More General Malignant Mesothelioma

General Myelodysplastic Syndrome

Sorry, there are no articles available for this cancer stage.

More General Myelodysplastic Syndrome

General Neuroblastoma

Sorry, there are no articles available for this cancer stage.

More General Neuroblastoma

General Renal Cancer

Sorry, there are no articles available for this cancer stage.

More General Renal Cancer

General Retinoblastoma

Sorry, there are no articles available for this cancer stage.

More General Retinoblastoma

General Sarcoma

Sorry, there are no articles available for this cancer stage.

More General Sarcoma

General Skin Cancer

Sorry, there are no articles available for this cancer stage.

More General Skin Cancer

General Thyroid Cancer

Pass it On: It’s National Thyroid Awareness Month (September 8, 2017)

The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in the front part of the neck. It produces, stores, and releases hormones that regulate vital body functions. Thyroid cancer happens when cells in the thyroid grow out of control.... Continue Reading

More General Thyroid Cancer

General Vaginal Cancer

Sorry, there are no articles available for this cancer stage.

More General Vaginal Cancer

H

Sorry, there are no articles available for this cancer stage.

More H

Hairy Cell Leukemia

Sorry, there are no articles available for this cancer stage.

More Hairy Cell Leukemia

Head and Neck Cancer

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN (July 19, 2018)

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include... Continue Reading

University of Colorado Study Suggests new Combination Treatment for Head and Neck Cancer (June 14, 2018)

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab. Often, the problem is that while treatments... Continue Reading

Managing Side Effects From EGFR Inhibitors (April 10, 2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading

Spring into Action For Oral, Head, and Neck Cancer Awareness Week! (April 3, 2018)

CancerConnect News: As the month of April brings head and neck cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer... Continue Reading

Guidelines for Human Papilloma Virus Testing in Head and Neck Carcinomas (February 6, 2018)

CancerConnect News:  The Centers for Disease Control and Prevention estimates that in the United States, there are more than 16,000 individuals diagnosed with Human Papilloma Virus (HPV)-positive OroPharyngeal Squamous Cell Carcinoma (OPSCC) each year... Continue Reading

More Head and Neck Cancer

Health and Wellness

Understanding Low Back Pain (December 1, 2017)

From theSpineCommunity Back pain is a symptom associated with over 60 different medical conditions.  These disorders involve a number of different organ systems.  A variety of healthcare professionals have expertise that can be useful in the diagnosis... Continue Reading

More Health and Wellness

Hepatocellular Carcinoma Liver Cancer

Sorry, there are no articles available for this cancer stage.

More Hepatocellular Carcinoma Liver Cancer

Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

HIV Related Cancers

Sorry, there are no articles available for this cancer stage.

More HIV Related Cancers

Hodgkin's Lymphoma

Clinical Trial Shows Best Outcomes to Date for Older Hodgkin Lymphoma Patients (September 18, 2018)

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy,... Continue Reading

FDA Approves Adcetris® in Combination with Chemotherapy for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma (March 22, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based... Continue Reading

Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma (March 1, 2018)

CancerConnect News: Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the precision cancer medicine Adcetris (brentuximab vedotin) had a 23-percent reduction in the risk of disease progression, death,... Continue Reading

More Hodgkin's Lymphoma

Hormonal Therapy

Sorry, there are no articles available for this cancer stage.

More Hormonal Therapy

I

Sorry, there are no articles available for this cancer stage.

More I

Indolent/Low Grade Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Indolent/Low Grade Non-Hodgkin's Lymphoma

Inflammatory Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Inflammatory Breast Cancer

Info Type

Sorry, there are no articles available for this cancer stage.

More Info Type

J

Sorry, there are no articles available for this cancer stage.

More J

K

Sorry, there are no articles available for this cancer stage.

More K

L

Sorry, there are no articles available for this cancer stage.

More L

Leukemia

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has... Continue Reading

CRISPR Enhances Cancer Immunotherapy (March 14, 2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells —... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (January 31, 2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)... Continue Reading

More Leukemia

Limited Disease Lung Cancer - Small Cell

Sorry, there are no articles available for this cancer stage.

More Limited Disease Lung Cancer - Small Cell

Liver Cancer

FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer (August 20, 2018)

The U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This approval was based on results from REFLECT, where LENVIMA... Continue Reading

Cyramza Improves Survival in Poor-Prognosis Liver Cancer (July 12, 2018)

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset... Continue Reading

Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer (February 20, 2018)

CancerConnect News:  Treatment with Cabometyx  (cabozantinib) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could offer a new treatment option for this patient population. ... Continue Reading

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer (February 15, 2018)

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About... Continue Reading

More Liver Cancer

Locally Advanced Stage III (C) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Locally Advanced Stage III (C) Prostate Cancer

Lung Cancer

Immune-mediated Nephritis Reported to Occur with Tecentriq® (August 30, 2018)

Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction. ... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless... Continue Reading

Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer (June 25, 2018)

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP... Continue Reading

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer (June 22, 2018)

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda... Continue Reading

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations (June 5, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or... Continue Reading

More Lung Cancer

Lung Cancer - Non-Small Cell

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless... Continue Reading

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations (June 5, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (April 11, 2018)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading

FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations (January 24, 2018)

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant... Continue Reading

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (January 17, 2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

More Lung Cancer - Non-Small Cell

Lung Cancer - Small Cell

Opdivo® (nivolumab) Approved for Treatment of Small Cell Lung Cancer (August 23, 2018)

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.1 About Small... Continue Reading

Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer (June 25, 2018)

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP... Continue Reading

More Lung Cancer - Small Cell

Lymphoma

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (July 12, 2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become... Continue Reading

More Lymphoma

M

Sorry, there are no articles available for this cancer stage.

More M

Management and Prevention of Anemia Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Anemia Supportive Care

Management and Prevention of Anorexia and Weight Loss Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Anorexia and Weight Loss Supportive Care

Management and Prevention of Bone Complications Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Bone Complications Supportive Care

Management and Prevention of Fatigue Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Fatigue Supportive Care

Management and Prevention of Mucositis Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Mucositis Supportive Care

Management and Prevention of Nausea and Vomiting Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Nausea and Vomiting Supportive Care

Management and Prevention of Neutropenia Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Neutropenia Supportive Care

Management and Prevention of Thrombocytopenia Supportive Care

Sorry, there are no articles available for this cancer stage.

More Management and Prevention of Thrombocytopenia Supportive Care

Mantle Cell Non-Hodgkin's Lymphoma

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (May 31, 2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma (August 9, 2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent... Continue Reading

More Mantle Cell Non-Hodgkin's Lymphoma

Melanoma

Targeted Combination Treatment for Melanoma now Available (September 10, 2018)

The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. About... Continue Reading

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring (August 17, 2018)

While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of... Continue Reading

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma (May 7, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected... Continue Reading

Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma (April 5, 2018)

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual... Continue Reading

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma (January 15, 2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected... Continue Reading

More Melanoma

Mesothelioma

Sorry, there are no articles available for this cancer stage.

More Mesothelioma

Metastatic Breast Cancer

FDA approves new treatment for certain advanced or metastatic breast cancers (October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading

More Metastatic Breast Cancer

Metastatic Stage IV (D) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Metastatic Stage IV (D) Prostate Cancer

Metastatic/Stage IVB Cervical Cancer

Sorry, there are no articles available for this cancer stage.

More Metastatic/Stage IVB Cervical Cancer

Miscellaneous

Sorry, there are no articles available for this cancer stage.

More Miscellaneous

Multiple Myeloma

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma (March 28, 2018)

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand... Continue Reading

CRISPR Enhances Cancer Immunotherapy (March 14, 2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells —... Continue Reading

Darzalex-Effective Treatment for Smoldering Multiple Myeloma (March 7, 2018)

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the American Society of Hematology (ASH). Multiple myeloma... Continue Reading

Kyprolis Improves Survival in Recurrent Multiple Myeloma (February 8, 2018)

CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease progressed or recurred following prior therapies.... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (February 7, 2018)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

More Multiple Myeloma

Myelodysplastic Syndrome

FDA Approves Vyxeos for Adults with Poor Prognosis AML (August 7, 2017)

The U.S. Food and Drug Administration granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes... Continue Reading

More Myelodysplastic Syndrome

Myeloproliferative Neoplasms MPN

Long Term Follow Up Shows Durability of Jakafi® Response in Patients with Polycythemia Vera (December 27, 2017)

CancerConnect News: Jakafi® (ruxolitinib) was initially reported to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than the best available therapy at the 56th American Hematology Society Annual Meeting in 2014.1,2... Continue Reading

Fedratinib May Represent New Option for Jakafi-Resistant Myelofibrosis (December 6, 2017)

Patients with myelofibrosis resistant or intolerant to Jakafi (ruxolitinib) may have an alternative treatment option with a novel JAK2-selective inhibitor fedratinib, according to the results of clinical study recently published in the medical journal... Continue Reading

Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia (November 22, 2017)

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant... Continue Reading

More Myeloproliferative Neoplasms MPN

N

Sorry, there are no articles available for this cancer stage.

More N

Neuroblastoma

Sorry, there are no articles available for this cancer stage.

More Neuroblastoma

News

Clinical Trial Shows Best Outcomes to Date for Older Hodgkin Lymphoma Patients (September 18, 2018)

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy,... Continue Reading

First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain (September 13, 2018)

Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, TX – September 13, 2018 – In the ongoing... Continue Reading

Targeted Combination Treatment for Melanoma now Available (September 10, 2018)

The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. About... Continue Reading

AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer (September 4, 2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved... Continue Reading

Immune-mediated Nephritis Reported to Occur with Tecentriq® (August 30, 2018)

Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction. ... Continue Reading

More News

Non-Hodgkin's Lymphoma

Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma (July 3, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase... Continue Reading

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (May 31, 2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading

FDA Approves Aliqopa for Relapsed Follicular Lymphoma (May 23, 2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who... Continue Reading

FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (May 21, 2018)

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients with relapsed or refractory diffuse large B-cell... Continue Reading

Keytruda Effective in Patients with Relapsed or Refractory Lymphoma (January 23, 2018)

CancerConnect News: Findings from the KEYNOTE-170 clinical trial Presented at the 59th American Society of Hematology (ASH) Annual Meeting suggest that the novel immunotherapy medication keytruda® (pembrolizumab) represents a new treatment option for... Continue Reading

More Non-Hodgkin's Lymphoma

O

Sorry, there are no articles available for this cancer stage.

More O

Osteosarcoma

Sorry, there are no articles available for this cancer stage.

More Osteosarcoma

Other News Topics (not Types of Cancer)

FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults (May 24, 2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of... Continue Reading

Lutathera Pepetide Receptor Radionuclide Therapy for NETs (May 3, 2018)

CancerConnect News: Lutathera (lutetium Lu 177 dotatate) was recently approved for the treatment of neuroendocrine tumors (NETs) that typically occur in the pancreas and gastrointestinal tract. This is the first time a radioactive drug, or radiopharmaceutical,... Continue Reading

FDA and CMS Collaborate to Make Novel Cancer Biomarker Test Available (December 7, 2017)

The U.S. Food and Drug Administration (FDA) has approved the F1CDx biomarker test designed to detect mutations in 324 genes and two genomic signatures in cancer patients. In a truly collaborative effort between the FDA and The Centers for Medicare &... Continue Reading

New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style (July 19, 2017)

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA... Continue Reading

More Other News Topics (not Types of Cancer)

Ovarian Cancer

About The National Ovarian Cancer Coalition (August 29, 2018)

Where do you go when you’re first delivered the news: “You have cancer”? For many women diagnosed with ovarian cancer, the answer is the National Ovarian Cancer Coalition (NOCC). With more than 80 chapters nationwide, a Web site (www.ovarian.org)... Continue Reading

Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient (June 18, 2018)

For many years ovarian cancer has been referred to as “the silent killer” due to its vague, ignored, or misdiagnosed symp­toms. Because of this and the lack of ear­ly-detection tools, ovarian cancer often goes undiagnosed until it has reached the... Continue Reading

PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer (May 16, 2018)

CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual... Continue Reading

Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer (April 9, 2018)

CancerConnect News: Rubraca® (rucaparib) has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.... Continue Reading

It’s in the Genes: Genetic Testing for Ovarian Cancer  (March 15, 2018)

What your DNA reveals and why it’s worth knowing CancerConnect News: Ovarian cancer is often dubbed as the “silent killer” of women. The symptoms are vague—including bloating, fatigue, irregular bleeding, frequent urination, and back pain1 —making... Continue Reading

More Ovarian Cancer

P

Sorry, there are no articles available for this cancer stage.

More P

Pain Management Supportive Care

Sorry, there are no articles available for this cancer stage.

More Pain Management Supportive Care

Pancreatic Cancer

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer (June 19, 2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has... Continue Reading

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study (April 18, 2018)

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim... Continue Reading

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer (March 5, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the... Continue Reading

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer (February 28, 2018)

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were... Continue Reading

Diagnosed with Pancreatic Cancer: 10 Tips on How to Get The Most From Your Doctor (December 26, 2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with pancreatic cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including... Continue Reading

More Pancreatic Cancer

Progressive Relapsed Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Progressive Relapsed Hodgkin's Lymphoma

Prostate Cancer

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (July 17, 2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading

Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer (May 1, 2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer? (February 22, 2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that... Continue Reading

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer (February 19, 2018)

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Erleada... Continue Reading

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation (February 14, 2018)

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif. ... Continue Reading

More Prostate Cancer

Q

Sorry, there are no articles available for this cancer stage.

More Q

R

Sorry, there are no articles available for this cancer stage.

More R

Radiopharmaceutical

Sorry, there are no articles available for this cancer stage.

More Radiopharmaceutical

Rectal Cancer

Managing Side Effects From EGFR Inhibitors (April 10, 2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (October 16, 2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients... Continue Reading

NSAIDs Decrease Risk of Colorectal Cancer (September 18, 2017)

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively... Continue Reading

More Rectal Cancer

Recurrent Anal Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Anal Cancer

Recurrent Bladder Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Bladder Cancer

Recurrent Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Breast Cancer

Recurrent Cervical Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Cervical Cancer

Recurrent Gastric Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Gastric Cancer

Recurrent Liver Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Liver Cancer

Recurrent Lung Cancer - Non-Small Cell

Sorry, there are no articles available for this cancer stage.

More Recurrent Lung Cancer - Non-Small Cell

Recurrent Lung Cancer - Small Cell

Sorry, there are no articles available for this cancer stage.

More Recurrent Lung Cancer - Small Cell

Recurrent Melanoma

Sorry, there are no articles available for this cancer stage.

More Recurrent Melanoma

Recurrent Multiple Myeloma

Sorry, there are no articles available for this cancer stage.

More Recurrent Multiple Myeloma

Recurrent Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Recurrent Non-Hodgkin's Lymphoma

Recurrent Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

More Recurrent Ovarian Cancer

Recurrent Pancreatic Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Pancreatic Cancer

Recurrent Testicular Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Testicular Cancer

Recurrent Uterine Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Uterine Cancer

Recurrent/Relapsed Rectal Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent/Relapsed Rectal Cancer

Refactory/Recurrent Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Refactory/Recurrent Prostate Cancer

Renal Cancer

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer (April 23, 2018)

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About... Continue Reading

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma (January 25, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential... Continue Reading

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma (January 5, 2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma... Continue Reading

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer (November 9, 2017)

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to... Continue Reading

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma (June 19, 2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy. ... Continue Reading

More Renal Cancer

Retinoblastoma

Sorry, there are no articles available for this cancer stage.

More Retinoblastoma

S

Sorry, there are no articles available for this cancer stage.

More S

Sarcoma

Nexavar Improves Survival for Patients with Rare Sarcomas (March 28, 2018)

Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug Nexavar (sorafenib tosylate) extended progression-free survival compared with a placebo. Progression-free survival... Continue Reading

Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers (August 8, 2017)

Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies for people with this malignancy.... Continue Reading

More Sarcoma

Screening/Prevention Anal Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Anal Cancer

Screening/Prevention Bladder Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Bladder Cancer

Screening/Prevention Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Breast Cancer

Screening/Prevention Cervical Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Cervical Cancer

Screening/Prevention Colon Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Colon Cancer

Screening/Prevention Esophageal Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Esophageal Cancer

Screening/Prevention Gastric Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Gastric Cancer

Screening/Prevention Leukemia

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Leukemia

Screening/Prevention Liver Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Liver Cancer

Screening/Prevention Lung Cancer - Non-Small Cell

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Lung Cancer - Non-Small Cell

Screening/Prevention Lung Cancer - Small Cell

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Lung Cancer - Small Cell

Screening/Prevention Melanoma

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Melanoma

Screening/Prevention Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Non-Hodgkin's Lymphoma

Screening/Prevention Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

More Screening/Prevention Ovarian Cancer

Screening/Prevention Pancreatic Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Pancreatic Cancer

Screening/Prevention Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Prostate Cancer

Screening/Prevention Rectal Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Rectal Cancer

Screening/Prevention Uterine Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Uterine Cancer

Skin Cancer

May Is National Skin Cancer Detection and Prevention Month (May 18, 2018)

Sun Valley, ID —OMNI Health  (OMNI) announces the launch of skin cancer programs for national skin cancer detection and prevention month. As the month of May brings skin cancer into focus, it’s time to increase public understanding of the disease,... Continue Reading

Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma (April 5, 2018)

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual... Continue Reading

PD-1 Antibody Cemiplimab Appears Promising for Treatment of Squamous Cell Carcinoma of the Skin (February 2, 2018)

Cemiplimab an investigational human antibody targeting PD-1 (programmed cell death protein 1), is yet another “checkpoint inhibitor” that was evaluated in 82 patients with advanced cutaneous squamous cell carcinoma (CSCC).  Early trial results suggest... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

More Skin Cancer

Skin Cancer Overview

Sorry, there are no articles available for this cancer stage.

More Skin Cancer Overview

Soft Tissue Sarcomas

Sorry, there are no articles available for this cancer stage.

More Soft Tissue Sarcomas

Stage I Cervical Cancer

Sorry, there are no articles available for this cancer stage.

More Stage I Cervical Cancer

Stage I Node Negative Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Stage I Node Negative Breast Cancer

Stage I Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

More Stage I Ovarian Cancer

Stage I-II Testicular Cancer

Sorry, there are no articles available for this cancer stage.

More Stage I-II Testicular Cancer

Stage I/Smoldering Myeloma Multiple Myeloma

Sorry, there are no articles available for this cancer stage.

More Stage I/Smoldering Myeloma Multiple Myeloma

Stage II-IV Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

More Stage II-IV Ovarian Cancer

Stage III Bladder Cancer

Sorry, there are no articles available for this cancer stage.

More Stage III Bladder Cancer

Stage III Melanoma

Sorry, there are no articles available for this cancer stage.

More Stage III Melanoma

Stage III Testicular Cancer

Sorry, there are no articles available for this cancer stage.

More Stage III Testicular Cancer

Stage IV (D)/Relapsed Colon Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV (D)/Relapsed Colon Cancer

Stage IV Anal Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV Anal Cancer

Stage IV Liver Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV Liver Cancer

Stage IV Melanoma

Sorry, there are no articles available for this cancer stage.

More Stage IV Melanoma

Stage IV Pancreatic Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV Pancreatic Cancer

Stage IV Rectal Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV Rectal Cancer

Stage IV Uterine Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV Uterine Cancer

Stage IV/Metastatic Bladder Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV/Metastatic Bladder Cancer

Stage IV/Recurrent Esophageal Cancer

Sorry, there are no articles available for this cancer stage.

More Stage IV/Recurrent Esophageal Cancer

Stages 0-I Bladder Cancer

Sorry, there are no articles available for this cancer stage.

More Stages 0-I Bladder Cancer

Stages I-II Anal Cancer

Sorry, there are no articles available for this cancer stage.

More Stages I-II Anal Cancer

Stages I-II Gastric Cancer

Sorry, there are no articles available for this cancer stage.

More Stages I-II Gastric Cancer

Stages I-II Melanoma

Sorry, there are no articles available for this cancer stage.

More Stages I-II Melanoma

Stages I-III Esophageal Cancer

Sorry, there are no articles available for this cancer stage.

More Stages I-III Esophageal Cancer

Stages I-III Liver Cancer

Sorry, there are no articles available for this cancer stage.

More Stages I-III Liver Cancer

Stages I-III Pancreatic Cancer

Sorry, there are no articles available for this cancer stage.

More Stages I-III Pancreatic Cancer

Stages I-III Rectal Cancer

Sorry, there are no articles available for this cancer stage.

More Stages I-III Rectal Cancer

Stages I-III Uterine Cancer

Sorry, there are no articles available for this cancer stage.

More Stages I-III Uterine Cancer

Stages I-IIIA Lung Cancer - Non-Small Cell

Sorry, there are no articles available for this cancer stage.

More Stages I-IIIA Lung Cancer - Non-Small Cell

Stages II-III Bladder Cancer

Sorry, there are no articles available for this cancer stage.

More Stages II-III Bladder Cancer

Stages II-III Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Stages II-III Breast Cancer

Stages II-III Multiple Myeloma

Sorry, there are no articles available for this cancer stage.

More Stages II-III Multiple Myeloma

Stages II-IVA Cervical Cancer

Sorry, there are no articles available for this cancer stage.

More Stages II-IVA Cervical Cancer

Stages III-IV Gastric Cancer

Sorry, there are no articles available for this cancer stage.

More Stages III-IV Gastric Cancer

Stages IIIB-IV Lung Cancer - Non-Small Cell

Sorry, there are no articles available for this cancer stage.

More Stages IIIB-IV Lung Cancer - Non-Small Cell

Stem Cell Transplant

Sorry, there are no articles available for this cancer stage.

More Stem Cell Transplant

Supportive

Sorry, there are no articles available for this cancer stage.

More Supportive

Supportive Care

Sorry, there are no articles available for this cancer stage.

More Supportive Care

Supportive Care Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Supportive Care Breast Cancer

T

Sorry, there are no articles available for this cancer stage.

More T

T-Cell Non-Hodgkin's Lymphoma

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (December 13, 2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma... Continue Reading

More T-Cell Non-Hodgkin's Lymphoma

Testicular Cancer

Sorry, there are no articles available for this cancer stage.

More Testicular Cancer

Throat Cancer

Head and Neck Cancer-What You Need to Know (August 14, 2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000... Continue Reading

More Throat Cancer

Thyroid Cancer

Loxo-292 Promising for Lung and Other “RET Fusion” Cancers (June 4, 2018)

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About... Continue Reading

Lower Thyroid Stimulating Hormone Levels Elevate Risk of Thyroid Cancer (September 20, 2017)

There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease. The Yale-led study, published in American Association for Cancer Research... Continue Reading

Pass it On: It’s National Thyroid Awareness Month (September 8, 2017)

The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in the front part of the neck. It produces, stores, and releases hormones that regulate vital body functions. Thyroid cancer happens when cells in the thyroid grow out of control.... Continue Reading

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer (June 6, 2017)

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer... Continue Reading

More Thyroid Cancer

Types of Cancer

Sorry, there are no articles available for this cancer stage.

More Types of Cancer

U

Sorry, there are no articles available for this cancer stage.

More U

Uncategorized

Sorry, there are no articles available for this cancer stage.

More Uncategorized

Uterine Cancer

Precision Cancer Treatment with Afinitor Encouraging in Uterine Cancer (April 4, 2018)

CancerConnect News: Combination therapy with Afinitor (everolimus) and Femara (letrozole) demonstrated encouraging activity in the treatment of advanced endometrial cancer, according to a report from the Society of Gynecologic Oncologists meeting this... Continue Reading

Uterine Cancer: The Next Immunotherapy Frontier? (January 30, 2018)

CancerConnect News: All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult... Continue Reading

More Uterine Cancer

V

Sorry, there are no articles available for this cancer stage.

More V

Vaginal Cancer

Sorry, there are no articles available for this cancer stage.

More Vaginal Cancer

Video

Sorry, there are no articles available for this cancer stage.

More Video

W

Sorry, there are no articles available for this cancer stage.

More W

X

Sorry, there are no articles available for this cancer stage.

More X

Y

Sorry, there are no articles available for this cancer stage.

More Y

Z

Sorry, there are no articles available for this cancer stage.

More Z